TransCode Therapeutics's total assets for Q3 2025 were $5.23M, a decrease of -36.77% from the previous quarter. RNAZ total liabilities were $3.80M for the fiscal quarter, a 79.39% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.